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Abstract
Background and purpose: The response to remission induction in elderly patients with acute
myeloid leukemia (AML) remains poor. The purpose of this paper is to evaluate the efficacy and
toxicity of a plant alkaloid, homoharringtonine, in combination with cytarabine as an induction
therapy for AML in elderly patients (≥60 years).
Results:  Twenty-three patients were treated with the HA regimen consisting of
homoharringtonine (2 mg/m2/day for 7 days) and cytarabine (Ara-C, 100 mg/m2/day for 7 days).
The overall response rate was 56.5% with complete remission (CR) rate of 39.1% and partial
remission of 17.4%. There was no early death in this cohort of patients. The estimated median
overall survival (OS) time of all patients was (12.0 ± 3.0) months. The estimated OS time of the CR
patients was 15 months. The estimated one-year OS rate of all patients treated with HA protocol
was (49.3 ± 13.5) %. The estimated one-year OS rate of the CR patients was (62.5 ± 17.1) %.
Conclusion: HA is a suitable induction regimen for elderly patients with AML, with relatively low
toxicity and reasonable response rate.
Introduction
The standard induction remission protocol in the treat-
ment of acute myeloid leukemia (AML) in adult patients
is 3-day daunorubicin (DNR) and 7-day cytarabine (Ara-
C) [1]. Over the 25 years in which this protocol has been
in use, a considerable number of strategies have been
developed with the goal of improving the efficacy of this
protocol, including the substitution of alternative anthra-
cyclines such as idarubicin [2,3]. Although the anthracy-
cline-based protocol has a high overall complete
remission (CR) rate in the treatment of AML, the outcome
in elderly AML patients remains unsatisfactory. Specifi-
cally, even though a high percentage of elderly AML
patients, including those with unfavorable prognosis,
respond to chemotherapy and survive longer than
patients who either refuse treatment or receive supportive
treatment alone, many proceed to develop serious and
often fatal complications [4,5].
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Homoharringtonine (HHT) is a plant alkaloid, derived
from the Cephalotuxus fortuneii tree, which for the past
30 years has been used in China for the treatment of AML
and chronic myeloid leukemia (CML). HHT and its ana-
logs, such as harringtonine, are inhibitors of protein syn-
thesis whose effects are both dose- and time-dependent.
HHT has significant potential synergistic effects with Ara-
C. Its cytotoxicity is cell-cycle specific, primarily affecting
cells in G1 and G2 phases. HHT is a suitable candidate for
the treatment of elderly patients, because it has relatively
mild extramedullary toxicity and lacks anthracyclin-like
myocardial toxicity [6-12].
We present here a retrospective analysis of the outcome of
HHT and Ara-C induction regimen (HA) for the treatment
of elderly AML patients admitted to this hospital.
Patients and methods
Clinical Data
We treated 23 newly diagnosed elderly (≥ 60 years) non-
M3 AML patients in this hematology centre between Jan-
uary 1996 and December 2008 with HHT-based protocol.
All patients fulfilled the following criteria: the diagnosis of
AML was established according to the standard French-
American -British (FAB) cytological and cytochemical cri-
teria; there was no major comorbidity, with normal liver,
kidney, heart, and lung function; and informed consent
was obtained. All patients underwent full clinical exami-
nations and assessment of blood counts. At the same
time, ALT, AST, bilirubin, blood glucose, alkaline phos-
phatase, and creatinine levels were determined before
each course of chemotherapy. Electrocardiograms were
performed on all patients before chemotherapy. Patients
with karyotypes of t(8;21), inv(16), or t(16;16) were con-
sidered to have good-risk cytogenetics; -5, -7, del(5q),
del(7q), del(9q), 11q23, abnormal 20q, abnormal 21q,
inv(3q), t(6;9), t(9;22), or complex cytogenetics (at least
three unrelated cytogenetic abnormalities) were consid-
ered to be poor-risk cytogenetics; normal cytogenetics and
other miscellaneous single abnormalities were considered
to be intermediate-risk cytogenetics.
Therapeutic Protocols
Each patient received at least one course of induction
chemotherapy with HA protocol (HHT 2 mg/m2 daily for
7 days as intravenous (IV) infusion over 4 h; and Ara-C
100 mg/m2 daily for 7 days as continuous IV infusion).
Upon recovery of the peripheral blood count, bone mar-
row (BM) aspiration was performed to assess the response
to treatment. For patients who did not achieve CR after
the first course of induction therapy, the same induction
protocol was repeated once if the decrease of BM blasts
was more than 60%. Otherwise, the patients were deemed
to be induction failure, and second-line induction therapy
was administered per treatment guidelines of this institu-
tion.
Granulocyte colony-stimulating factor (5 mcg/kg) was
administered subcutaneously daily if the neutrophil
count fell below 0.5–1.0 × 109/L after chemotherapy, and
terminated when the neutrophil count rose above 1.0–2.0
× 109/L. Blood and platelet transfusion and anti-infection
treatment were given according to standard protocols.
Consolidation therapy was administered after the
achievement of CR as the following: HA regimen as
described above, DA (DNR, 30 mg/m2 daily for 3 days,
Ara-C 100 mg/m2 daily for 7 days) or IDA (idarubicin, 6
mg/m2 daily for 3 days, Ara-C 100 mg/m2 daily for 7
days), EA (etoposide, 60 mg/m2 daily for 5 days, Ara-C
100 mg/m2 daily for 7 days) and MA (mitoxantrone 6 mg/
m2 daily for 3 days, Ara-C 100 mg/m2 daily for 7 days) by
turns. In patients older than 70 years, or those who expe-
rienced very severe complications, the doses of chemo-
therapeutic drugs were reduced by 20–50 percent, and/or
the duration time of chemotherapy was shortened to 5
days.
Response criteria
CR was defined as normal hematopoiesis of bone mar-
row, including neutrophils ≥ 1.5 × 109/L, platelets ≥ 100 ×
109/L, blasts in bone marrow ≥ 5%, no blasts in peripheral
blood, and the absence of extramedullary disease. PR was
defined by bone marrow blasts between 5% and 20% and
peripheral blood blasts < 5%, with neutrophils > 1.5 ×
109/L and platelets > 50 × 109/L. NR (no response) was
assigned to patients who did not fulfill the above criteria.
Early toxic death (ED) was defined as death following
induction treatment before it was possible to assess the
remission status. Overall survival (OS) was defined as the
time from the start of treatment to death by any cause or
to the termination of observation.
Statistical methods
Survival analysis was performed by the Kaplan-Meier
method using the SPSS 13.0 software.
Results
Characteristics of the patients
Characteristics of the patients at the time of diagnosis are
listed in Table 1. The median age of these patients was 70
(60–84) years. Seven patients had history of myelodys-
plastic syndrome (MDS). The median WBC count was 5.0
(0.7–263.3) × 109/L, and blast cells in bone marrow was
63.0 (20.0–92.5)%. Ten patients had cytogenetics data.
Among them, 2 patients had poor-risk karyotypes; 8 had
intermediate-risk karyotypes. The major FAB subtypes
were M4 (5/23) and M5 (7/23).
Response
Among patients treated with HA protocol, 39.1% (9/23)
achieved CR, 17.4% (4/23) achieved PR, with the overall
response (OR) of 56.5% (13/23).Journal of Hematology & Oncology 2009, 2:32 http://www.jhoonline.org/content/2/1/32
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Three of the 7 patients who had AML secondary to MDS
achieved CR and another one achieved PR. Only 1 of the
4 patients whose white blood cell count exceeded 50 ×
109/L at the time of diagnosis achieved CR. Two patients
refused to accept consolidation therapy after CR. The rest
of the patients received a median of 4 (1–12) courses of
consolidation therapy after CR.
Toxicity
The most common toxicity during the induction phase
was myelosuppression. The median time from the end of
chemotherapy to the neutrophil count reaching 1.5 × 109/
L was 16 (range: 7–45) days and the median time to the
platelet reaching 50 × 109/L was 15 (7–40) days in 19
patients; in the other 4 patients blood cell counts never
recovered to the above level. The median duration of anti-
infection (fungus or bacteria) treatment was 12 (0–46)
days. The median amount of platelet transfusion was 20
(0–110) units, and red blood cell transfusion 4 (0–10)
units. There was no treatment-related mortality. Non-
hematological toxicities were mild, mainly nausea or
emesis of I-II degree. There was no severe cardiotoxicity
observed in this cohort of patients.
Follow-up results
The observation was terminated when the patient died,
missing, or the disease free survival time reaching three
years. The estimated median OS time of all patients was
12.0 ± 3.0 months. The estimated OS time of the CR
patients were 15 months. The estimated one-year OS rate
of all patients were 49.3 ± 13.5% (Figure 1). The estimated
one-year OS rate of CR patients was 62.5 ± 17.1%.
Discussion
Age affects survival significantly in AML patients. Elderly
AML patients are generally offered palliative treatment
instead of induction chemotherapy. However, studies by
Pigneus and other research groups suggest that elderly
patients with AML should not be excluded systematically
Table 1: Clinical data of 23 patients treated with induction chemotherapy of homoharringtonine and cytarabine.
Case Sex/year History of MDS(+/-) WBC (×109) BM leukemic cells(%) karyotype FAB subtype
1 F/60 - 7.3 58.0 t(7;11), -21/-17 M2
2M / 7 0 + 2 . 7 3 1 . 0 - M 1
3 M/61 - 102.0 76.0 - M5
4 F/70 - 60.4 93.0 - M4
5M / 7 5 + 1 . 5 8 1 . 0 N o r m a l M 6
6M / 6 0 + 0 . 7 3 8 . 0 - M 2
7 F/60 - 1.3 70.5 Normal- M5
8M / 6 1 - 1 . 2 6 0 . 0 N o r m a l M 5
9 M/71 - 58.9 76.0 - M4
10 M/75 + 24.3 20.0 Normal M4
11 M/63 - 1.3 64.0 - M5
12 F/60 + 31.8 48.0 t(11;19) M2
13 M/74 - 263.3 85.0 - M4
14 M/70 - 6.2 96.0 +1(?20q-) M1
15 M/69 - 21.7 76.0 7q-,11q- M1
16 M/72 - 15.8 85.0 Normal M5
17 F/70 + 1.5 20.0 - M4
18 F/72 - 2.1 31.0 - M7
19 F/66 - 3.0 46.0 - M6
20 M/71 - 1.1 35.0 - M2
21 M/84 - 11.1 72.0 Normal M1
22 M/72 - 1.3 66.0 - M5
23 F/70 + 4.0 35.0 - M5
Probability of overall survival in elderly patients with AML  undergoing induction chemotherapy of homoharringtonine  and cytarabine Figure 1
Probability of overall survival in elderly patients with 
AML undergoing induction chemotherapy of homo-
harringtonine and cytarabine.Journal of Hematology & Oncology 2009, 2:32 http://www.jhoonline.org/content/2/1/32
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from intensive chemotherapy protocols. They found that
elderly patients who received chemotherapy achieved
longer survival times than those who refused treatment or
received supportive treatment alone. Unfortunately, many
of these patients suffer serious or fatal complications dur-
ing treatment [13-20]. For example, Alymara et al.
reported a study in which 23.7% of the 38 patients older
than 60 years of age who received chemotherapy using
idarubicin (8 mg/m2 for 3 days), Ara-c (100 mg/m2 for 5
days), and etoposide (75 mg/m2 for 5 days) achieved CR,
while 34.2% patients achieved PR. However, during the
treatment, 42.1% of their patients died of infection, cere-
brovascular or gastrointestinal hemorrhage, or acute myo-
cardial infarction [15].
An Eastern Collaborative Oncology Group study rand-
omized elderly AML patients to remission induction ther-
apy with either daunorubicin, idarubicin, or
mitoxantrone along with a standard dose of Ara-C and
priming with GM-CSF. The outcomes were not signifi-
cantly different in the three arms, with CR rates ranging
from 40% to 46%, median survival 8 months, and a 15%
treatment related death [21].
In the present retrospective study, we have studied the
outcomes in elderly patients who were treated with induc-
tion chemotherapy of HA protocol in this hospital. In the
previous study of Jin et al [7], a homoharritonine-based
regimen (HAA: homoharritonine 4 mg/m2/day, days 1–3;
cytarabine 150 mg/m2/day, days 1–7; aclarubicin 12 mg/
m2/day, days 1–7) was shown to be a well-tolerated, effec-
tive induction regimen in young adult patients with de
novo AML. Eighty-three percent of patients achieved CR,
the estimated 3 years OS rate was 53%, whereas for
patients with M5, the estimated OS rate at 3 years was
75%. In our study, the response results of HA are compa-
rable with these and other reported results in elderly
patients with AML [15-21]. The response rates of HA are
also comparable with the data of elderly patients treated
with DA (daunorubicin 40 mg/m2/d for 3 days; Ara-c, 100
mg/m2/day for 7 days) or IDA (idarubicin 6 mg/m2/d for
3 days; Ara-c, 100 mg/m2/day for 7 days) protocols in our
center during the same period. The differences in CR, OR
rates and estimated median OS times between HA, DA,
IDA groups were not statistically significant (Table 2). The
results suggest that HA is also an effective induction regi-
men with less toxicity in elderly patients with AML. Fur-
thermore, 3 of the 7 patients with AML secondary to MDS
achieved CR, suggesting HA regimen is also effective in
elderly patients with AML secondary to MDS. The toxicity
of HA regimen protocol was relatively low. There was no
early death in these patients treated with HA regimen and
no severe cardiotoxicity was shown, while the ED rate
within the first month of induction therapy in patients
treated with DA and IDA from this same hospital was high
(19.5% and 23.8%, respectively, Table 2), suggesting that
HA regimen may be better tolerated in elderly patients
with AML. A prospective study on this regimen for elderly
AML patients is warranted.
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